Skip to main content
. 2022 Aug 5;14(1):21–27. doi: 10.1007/s13193-022-01611-w

Table 4.

The follow-up data of the patients who had neoadjuvant therapy for non-metastatic gastric GISTs

Patients, n = 34 (%)
Adjuvant imatinib
  No 5 (14.7%)
  Yes 29 (85.3%)
Duration of adjuvant therapy (months; mean ± SD) 18.21 ± 12.497
The overall survival (months; mean ± SD) 37 ± 23.25
The disease-free survival (months; mean ± SD) 34.53 ± 20.18
Recurrence

  No

  Yes

32 (94.1%)

2 (5.9%)